Global Generics

Global Generics division commercializes Finished Dosage Forms in highly regulated markets such as North America, EU and Australia.

RPG Life Sciences established its operations in the regulated market back in 2004 and in a short span of 7 years it has achieved significant growth in the European market in the chosen areas of therapeutic categories. Global Generics division provides strengths in the Immunosuppressant therapy to the company.
 
Azathioprine is a flagship product for RPG Life Sciences which has dominant markets share worldwide in the Immunosuppressant therapy. Company plans to expand its footprint in the same therapy with complex molecules to represent it in all the dosage forms.
 
Outstanding service levels can be attributed to the dedicated customer service teams put in place to ensure smooth transition of products from the manufacturing locations in India to the farthest regions of Canada and European territories. RPGLS' long business relationships with major Generic companies in the world are testimonies of its strong customer focus.